BPC-157 vs TB-500: two different molecules

These two are named together so routinely that a lot of people assume they are related compounds, or two grades of the same thing. They are neither. This is what separates them, for material supplied for laboratory research use only.

Different origins

BPC-157 is a synthetic peptide whose sequence derives from a protein found in gastric juice — the name stands for Body Protection Compound. It is a pentadecapeptide: fifteen amino acids, which is short by any standard.

TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in cell structure. TB-500 is not thymosin beta-4 itself; it is a fragment of it, which is a distinction that gets flattened constantly in vendor copy and matters when reading a report.

So: one is derived from a gastric protein, the other from a thymosin. There is no family relationship.

Different sizes, and why the number on a report differs

BPC-157 is the larger of the two. On the Janoshik reports for our own blend, TB-500 is identified with its molecular mass printed alongside it — 889 Da — which is the kind of detail that only appears when the laboratory has measured mass rather than assumed identity.

That number is worth knowing for a practical reason. When a blend report lists two compounds at different concentrations, the ratio is not arbitrary: it reflects what was formulated, and different masses mean the same milligram figure represents a different number of molecules for each. A report that gives mass and concentration lets you check the formulation. One that gives neither does not.

Different mechanisms in the literature

The research pathways are genuinely distinct.

BPC-157 is examined in connection with angiogenesis — the formation of new blood vessels — and with fibroblast migration, the movement of the cells involved in connective tissue structure. Much of the published work concerns the gastrointestinal tract, which follows from where the sequence originates.

TB-500 is examined in connection with actin binding. Actin is one of the structural proteins inside cells, and the thymosin beta-4 family's documented role is in regulating it. That is a cytoskeletal mechanism rather than a vascular one.

These are different questions being asked of different molecules. Neither is a stronger version of the other, and the research literatures barely overlap.

So why are they sold together?

Honestly: because the two mechanisms are studied in adjacent contexts, and because a single container holding both removes the handling problem of running two.

We supply them as a pre-mixed pair for that second reason. It is a format decision, not a claim that the combination does something the separate compounds do not — and there is no research standing behind us that would support such a claim if we wanted to make one.

Our BPC-157 + TB-500 40 mg set holds 20 mg of each. The batch report lists both compounds with their measured concentrations, which is the thing to check: in a blend there is no single purity figure, and why a blend report has no purity percentage explains why, and what the numbers you do get actually establish.

What neither of them is

Neither compound is approved or licensed anywhere. Both appear on anti-doping lists. Both are supplied here strictly for laboratory research, and nothing on this site describes what either does in a person, because an unlicensed product may not be advertised with a medicinal claim.

The regulatory position for each is set out in FDA approved, MHRA licensed, or neither, and the anti-doping position in which peptides are on the WADA prohibited list.